Zonegran

Phase 3

Eisai (ESALY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Binge Eating Disorder Associated With Obesity

View Full Landscape

Drug Information

Target Indication

Binge Eating Disorder Associated With Obesity

Clinical Trial

NCT00221442

Last updated: 8/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/10/2005

Zonegran

Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ESALY

Eisai

Healthcare•North America•NASDAQ

Related Pipeline

Eperisone hydrochloride and Diclofenac sodiumPhase 3

Acute Musculoskeletal Spasm Due to Low Back Pain

T-614Phase 3

Rheumatoid Arthritis